Skip to main content
MedPacto, Inc. logo

MedPacto, Inc. — Investor Relations & Filings

Ticker · 235980 ISIN · KR7235980000 KO Manufacturing
Open in API
Filings indexed 262 across all filing types
Latest filing 2020-03-23 Declaration of Voting R…
Country KR South Korea
Listing KO 235980

About MedPacto, Inc.

http://www.medpacto.com/eng/

MedPacto, Inc. is a clinical-stage biotechnology company specializing in the discovery and development of first-in-class therapies. The company leverages a biomarker-driven and genome-based platform to create personalized treatments, aiming to advance precision medicine. Its primary therapeutic areas include oncology and autoimmune diseases, with pipeline expansion into metabolic and bone joint disorders. MedPacto's research focuses on novel mechanisms, such as modulating the tumor microenvironment, to address incurable diseases and overcome the limitations of existing treatments.

Recent filings

Filing Released Lang Actions
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled '정기주주총회결과' (Annual General Meeting Results) and provides a detailed breakdown of the resolutions passed during the meeting, including financial statement approval, director/auditor compensation limits, and stock option grants. This is an official record of the voting outcomes from a general meeting, which falls under the 'Declaration of Voting Results & Voting Rights Announcements' category.
2020-03-23 Korean
주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 95% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on the Granting of Stock Options) submitted to the Financial Services Commission/Korea Exchange. It details the issuance of stock options to employees and external experts, including the number of shares, exercise price, and valuation methodology. This type of disclosure regarding capital structure changes and equity-based compensation falls under the category of share issues or capital changes.
2020-03-23 Korean
기타경영사항(특허권취득)(자율공시)(신규한 피리미딘화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 암 및 염증질환의 예방 또는 치료용 약학적 조성물)
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure (자율공시) from MedPacto regarding the acquisition of a patent for a new pyrimidine compound used in cancer and inflammatory disease treatment. It details the patent name, content, and utilization plan. Since it does not fit into specific financial reporting categories like 10-K, IR, or ER, and is a regulatory disclosure of a corporate event, it falls under the general regulatory filing category.
2020-03-20 Korean
감사보고서제출
Audit Report / Information Classification · 98% confidence The document is titled '감사보고서 제출' (Submission of Audit Report) and provides a summary of financial data, audit opinions, and key financial metrics (assets, liabilities, profit/loss) as required by regulatory filing standards in Korea. It is a short, structured announcement confirming that the audit report has been submitted to the regulator, rather than the full, multi-page audit report document itself. Following the 'Menu vs Meal' rule, this is classified as a Report Publication Announcement. FY 2019
2020-03-10 Korean
[기재정정]기업설명회(IR)개최
Investor Presentation Classification · 95% confidence The document is a regulatory filing (a 'correction report' or '정정신고') from MedPacto announcing the cancellation of a previously scheduled Investor Relations (IR) event due to COVID-19. Since it is a formal regulatory announcement regarding the status of a corporate event rather than the presentation materials themselves, it falls under the category of general regulatory filings.
2020-03-10 Korean
주주총회소집결의
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) for MedPacto, dated 2020-02-28. It outlines the date, location, and agenda items (such as financial statement approval, director/auditor compensation, and stock option grants) for the upcoming Annual General Meeting. This document serves as the official proxy solicitation and meeting notice provided to shareholders to inform them of the meeting and the items to be voted upon.
2020-02-28 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.